The clinical study to explore the effects of DPP-4 inhibitors on responses of lipid

The clinical study to explore the effects of DPP-4 inhibitors on responses of lipid - The clinical study to explore the effects of DPP-4 inhibitors on responses of lipid

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020968

Enrollment

Registered

2016-02-11

Start date

2014-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

Anagliptin 100 mg twice a day for 6months Sitagliptin 50 mg once a day for 6months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Outpatients with type 2 diabetes (HbA1c:6.5-10%) who were attended to Showa University Hospital (Tokyo, Japan) 2.Patients who are 20-85 years old 3.Patients who themselves can voluntarily provide consent to participate in this study

Exclusion criteria

Exclusion criteria: 1.Patients who are acute disease 2.Patients who are past history of hypersensitivity to anagliptin 3.Pregnant or woman of child-bearing potential 4.Patients who are stage5 of diabetic nephropathy 5.Patients who are judged as inappropriate for inclusion by phsicians

Design outcomes

Primary

Measure	Time frame
small dense LDL and large LDL particles, HDL2 and 3 particles, Apoprotein, MDA-LDL, cholesterol absorption marker, cholesterol biosynthesis marker	—

Secondary

Measure	Time frame
plasma glcose, central blood pressure high-sensitivity CRP U-LFABP U-alb	—

Countries

Japan

Contacts

Public ContactToshiyuki Hayashi

Showa University School of Medicine Division of Diabetes and Endocrinology, Department of Internal Medicine

t-hayashi@med.showa-u.ac.jp03-3784-8000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026